AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,549,175 | +59.8% | 143,401 | +82.9% | 0.00% | – |
| Q2 2023 | $2,220,543 | -46.7% | 78,409 | -56.8% | 0.00% | -100.0% |
| Q1 2023 | $4,166,712 | +128.9% | 181,398 | +179.8% | 0.00% | – |
| Q4 2022 | $1,820,679 | -47.4% | 64,839 | -47.0% | 0.00% | – |
| Q3 2022 | $3,460,000 | +186.4% | 122,353 | +124.5% | 0.00% | – |
| Q2 2022 | $1,208,000 | -67.9% | 54,500 | -57.8% | 0.00% | – |
| Q1 2022 | $3,760,000 | -66.9% | 129,159 | -62.6% | 0.00% | – |
| Q4 2021 | $11,344,000 | -46.5% | 345,082 | -24.8% | 0.00% | -100.0% |
| Q3 2021 | $21,188,000 | -18.2% | 459,115 | -2.3% | 0.00% | -25.0% |
| Q2 2021 | $25,889,000 | +32.9% | 469,752 | +24.6% | 0.00% | +33.3% |
| Q1 2021 | $19,476,000 | -44.7% | 377,138 | -53.6% | 0.00% | 0.0% |
| Q4 2020 | $35,250,000 | +444.4% | 813,508 | +339.8% | 0.00% | +200.0% |
| Q3 2020 | $6,475,000 | -51.0% | 184,988 | -25.1% | 0.00% | -75.0% |
| Q2 2020 | $13,202,000 | +19.1% | 246,852 | -21.0% | 0.00% | +33.3% |
| Q1 2020 | $11,081,000 | -50.4% | 312,299 | -33.3% | 0.00% | -50.0% |
| Q4 2019 | $22,349,000 | -12.1% | 468,044 | -40.4% | 0.01% | -33.3% |
| Q3 2019 | $25,425,000 | -62.5% | 784,746 | -42.3% | 0.01% | +12.5% |
| Q2 2019 | $67,869,000 | +140.2% | 1,360,646 | +224.8% | 0.01% | -27.3% |
| Q1 2019 | $28,250,000 | +102.3% | 418,900 | +38.3% | 0.01% | +120.0% |
| Q4 2018 | $13,964,000 | -26.8% | 302,842 | +22.4% | 0.01% | -16.7% |
| Q3 2018 | $19,080,000 | -18.7% | 247,400 | -11.2% | 0.01% | -14.3% |
| Q2 2018 | $23,469,000 | +2.2% | 278,639 | -0.8% | 0.01% | -12.5% |
| Q1 2018 | $22,961,000 | +131.1% | 280,767 | +61.6% | 0.01% | +100.0% |
| Q4 2017 | $9,934,000 | -31.9% | 173,751 | -20.4% | 0.00% | -33.3% |
| Q3 2017 | $14,579,000 | +68.0% | 218,405 | +29.5% | 0.01% | +50.0% |
| Q2 2017 | $8,680,000 | -50.6% | 168,700 | -43.9% | 0.00% | -50.0% |
| Q1 2017 | $17,567,000 | +8.4% | 300,800 | -22.6% | 0.01% | 0.0% |
| Q4 2016 | $16,210,000 | -16.3% | 388,437 | +5.9% | 0.01% | -11.1% |
| Q3 2016 | $19,367,000 | +67.3% | 366,675 | +32.7% | 0.01% | +50.0% |
| Q2 2016 | $11,577,000 | +32.5% | 276,339 | +28.4% | 0.01% | +50.0% |
| Q1 2016 | $8,740,000 | -48.4% | 215,253 | -17.4% | 0.00% | -50.0% |
| Q4 2015 | $16,922,000 | -3.1% | 260,655 | +5.3% | 0.01% | +14.3% |
| Q3 2015 | $17,472,000 | -56.3% | 247,520 | -31.2% | 0.01% | -56.2% |
| Q2 2015 | $39,964,000 | +11.0% | 359,576 | -5.9% | 0.02% | -5.9% |
| Q1 2015 | $36,019,000 | -11.7% | 381,966 | +4.9% | 0.02% | +6.2% |
| Q4 2014 | $40,800,000 | +178.3% | 364,147 | +52.4% | 0.02% | +166.7% |
| Q3 2014 | $14,661,000 | +372.3% | 238,987 | +252.8% | 0.01% | +200.0% |
| Q2 2014 | $3,104,000 | – | 67,747 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |